While REM Sleep Behavior disorder (RBD) has been linked with synucleinopathies, difficulties persist in clinically convenient diagnostic tools which can differentiate between underlying diseases. Identifying markers in the gait of RBD patients may ease the diagnostic process and indicate potential or status for developing more severe disorders. Individuals were referred to Movement Disorders Center of Arizona (MDCA) by a sleep specialist with a confirmed diagnosis of RBD, or those who were clinically indicated after questioning. All participants underwent a skin-biopsy test for α-synuclein, I-ioflupane dopamine transporter(DAT) scan, and had their gait velocity, cadence and stride dynamics assessed by an automated gait analysis system.